V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007611 | 10005473 | 1.66 | 101.7 | Palliative (P) | 2019-09-27 | 2019-10-11 | RUXOLITINIB | N | N | 10365102 | DHAP - R |
| 10007612 | 10005474 | 1.73 | 77.8 | Palliative (P) | 2017-08-25 | 2017-08-26 | R Chlorambucil | 02 | N | 10367123 | ENRICH TRIAL |
| 10007613 | 10005475 | null | 61.6 | Curative (C) | 2018-04-05 | 2018-05-09 | Docetaxel + Nintedanib | Y | Y | 10369878 | FLAG + IDARUBICIN |
| 10007614 | 10005477 | 1.79 | null | Neo-adjuvant (N) | 2018-10-06 | 2018-10-06 | RIALTO TRIAL | N | null | 10370151 | INCA TRIAL |
| 10007615 | 10005479 | 1.53 | 57 | Curative (C) | 2017-12-07 | 2017-12-07 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10371240 | FEC |
| 10007616 | 10005480 | 1.66 | 67.8 | Curative (C) | 2017-12-09 | 2018-04-29 | Methotrexate intrathecal | N | N | 10371251 | CAV |
| 10007617 | 10005481 | 1.71 | 82.6 | null | 2019-07-25 | 2019-07-25 | Methotrexate intrathecal | 01 | null | 10372122 | CHLORAMBUCIL |
| 10007618 | 10007717 | 1.78 | 63.6 | Palliative (P) | 2016-09-19 | 2016-09-23 | Bendamustine +/- Prednisolone | N | N | 10372953 | CAPECITABINE + IRINOTECAN |
| 10007619 | 10009048 | 1.68 | 65 | Palliative (P) | 2019-06-12 | 2019-07-03 | PMitCEBO-R | 2 | N | 10372973 | EOX |
| 10007620 | 10009202 | 1.71 | 103 | Adjuvant (A) | 2018-04-23 | 2018-04-28 | Cetuximab + FLUOROURACIL + OXALIPLATIN | N | N | 10373534 | BEXAROTENE |
| 10007621 | 10005482 | null | 84.6 | Palliative (P) | 2018-12-28 | 2019-02-22 | NIVOLUMAB | N | Y | 10374253 | HYDROXYCARBAMIDE |
| 10007622 | 10005483 | null | 91.1 | Palliative (P) | 2017-12-29 | 2018-01-02 | Capecitabine (14 day) + Irinotecan | Y | N | 10374253 | EOX |
| 10007623 | 10005484 | 1.74 | 59.75 | Adjuvant (A) | 2015-07-16 | 2015-07-23 | MUK 7 TRIAL | 2 | N | 10376328 | BORTEZOMIB |
| 10007624 | 10005484 | 1.59 | null | Adjuvant (A) | 2018-03-06 | 2018-03-07 | Erlotinib | 02 | N | 10376328 | CAPECITABINE + IRINOTECAN |
| 10007625 | 10005486 | null | 58.1 | Palliative (P) | 2019-04-13 | 2019-04-13 | EC | 2 | N | 10379193 | MPT |
| 10007626 | 10005486 | 1.86 | 104.3 | Adjuvant (A) | 2018-06-12 | 2018-06-17 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | N | 10379193 | CETUXIMAB |
| 10007627 | 10008672 | null | 54.2 | Curative (C) | 2019-01-24 | 2019-02-01 | Cyclophosphamide oral | N | N | 10399056 | METHOTREXATE HIGH DOSE |
| 10007628 | 10005487 | 1.67 | 91 | Curative (C) | 2019-11-11 | 2019-11-15 | REMODLB TRIAL | 2 | null | 10401494 | CHLORAMBUCIL + RITUXIMAB |
| 10007629 | 10005489 | 1.55 | 58.8 | Curative (C) | 2016-08-27 | 2016-08-29 | IMATINIB | N | N | 10403034 | DOCETAXEL + NINTEDANIB |
| 10007630 | 10005491 | 1.6 | 65.9 | null | 2017-07-23 | 2017-07-23 | Topotecan (oral) | N | N | 10403803 | CISPLATIN + FLUOROURACIL |
| 10007631 | 10005492 | 1.85 | 91 | Palliative (P) | 2019-09-10 | 2019-09-12 | Ixazomib + Lenalidomide | N | N | 10415074 | BEP |
| 10007632 | 10005493 | 1.74 | null | Palliative (P) | 2018-07-19 | 2018-07-29 | Irinotecan | N | null | 10415563 | CYTARABINE |
| 10007633 | 10005493 | 1.87 | 0 | Curative (C) | 2019-03-08 | 2019-05-10 | HCX (Cape + Cisp + Tras) - Load | Y | N | 10415563 | CETUXIMAB + RT |
| 10007634 | 10005494 | 1.7 | null | Adjuvant (A) | 2019-04-06 | 2019-04-06 | FCR Oral - Cycle 1 | N | N | 10415778 | PERTUZUMAB + TRASTUZUMAB |
| 10007635 | 10005496 | 1.09 | 61.8 | null | 2018-08-14 | 2018-08-22 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10415858 | FLUOROURACIL + MITOMYCIN + RT |
| 10007636 | 10005496 | 1.75 | 65.1 | Palliative (P) | 2018-07-17 | 2018-07-17 | OXALIPLATIN + MDG + PANITUMUMAB | N | N | 10415858 | BORTEZOMIB + THALIDOMIDE |
| 10007637 | 10005497 | 1.79 | 104 | Palliative (P) | 2017-07-20 | 2017-07-23 | FLAG + Idarubicin | N | N | 10417434 | BEAM |
| 10007638 | 10007724 | 1.76 | 61.7 | Adjuvant (A) | 2017-11-23 | 2017-11-26 | Vemurafenib | 02 | N | 10418698 | MPV |
| 10007639 | 10005499 | 1.7 | 135.5 | Adjuvant (A) | 2017-01-17 | 2017-01-24 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 10419975 | CABAZITAXEL |
| 10007640 | 10005500 | 1.81 | null | null | 2019-07-02 | 2019-07-19 | DABRAFENIB + TRAMETINIB | N | null | 10420372 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE |
| 10007641 | 10005501 | 1.7 | 79.6 | Palliative (P) | 2019-03-21 | 2019-03-21 | Cisplatin 7 day | 02 | null | 10420706 | ECX |
| 10007642 | 10005503 | 0 | 80.45 | Curative (C) | 2019-02-22 | 2019-03-22 | CISPLATIN + VINORELBINE | N | N | 10421057 | METHOTREXATE |
| 10007643 | 10007726 | 1.8 | 95.8 | Adjuvant (A) | 2016-07-16 | 2016-08-01 | ABVD | 2 | N | 10421623 | CETUXIMAB + IRINOTECAN + MDG |
| 10007644 | 10007726 | 1.74 | 67.4 | Palliative (P) | 2018-07-03 | 2018-07-03 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | Y | 10421623 | OSIMERTINIB |
| 10007645 | 10005504 | 1.77 | 81.9 | Disease modification (D) | 2018-04-26 | 2018-12-19 | Mini BEAM | N | N | 10421914 | MYELOMA XI TRIAL |
| 10007646 | 10005506 | 1.79 | null | Palliative (P) | 2018-02-09 | 2018-02-16 | PMitCEBO-R | 2 | N | 10422286 | AFATINIB |
| 10007647 | 10005507 | 1.8 | 94.9 | null | 2016-09-12 | 2016-10-25 | CISPLATIN + FLUOROURACIL | 2 | Y | 10422338 | DHAP - R |
| 10007648 | 10005509 | 1.81 | 82.1 | Curative (C) | 2016-11-11 | 2016-11-16 | Folfirinox | 2 | N | 10422820 | CARBOPLATIN + RT |
| 10007649 | 10005511 | 1.83 | 99.9 | Curative (C) | 2016-11-16 | 2016-11-16 | CISPLATIN + GEMCITABINE | N | N | 10422821 | BEAM + ALEMTUZUMAB |
| 10007650 | 10005512 | 1.6 | 64.6 | Neo-adjuvant (N) | null | 2018-08-11 | FEC | 1 | null | 10423299 | DOCETAXEL + NINTEDANIB |
| 10007651 | 10005513 | 1.62 | null | Palliative (P) | 2017-11-19 | 2017-11-19 | PERTUZUMAB + TRASTUZUMAB | 2 | null | 10424273 | CAP + RT |
| 10007652 | 10007728 | 0 | 95.6 | Adjuvant (A) | 2018-01-09 | 2018-01-13 | Vemurafenib | N | N | 10424306 | CHLORAMBUCIL |
| 10007653 | 10008675 | 0 | 73.1 | Palliative (P) | 2019-02-21 | 2019-09-11 | METHOTREXATE | 01 | N | 10424915 | CETUXIMAB + IRINOTECAN + MDG |
| 10007654 | 10005515 | 1.7 | 74.5 | Palliative (P) | 2017-08-18 | 2017-08-19 | Bortezomib +/- Dexamethasone | 2 | N | 10425028 | REMODL TRIAL |
| 10007655 | 10007730 | null | 72.2 | Curative (C) | 2014-06-05 | 2015-02-26 | Doxorubicin + Ifosfamide | 02 | Y | 10425528 | CAPECITABINE + CARBOPLATIN |
| 10007656 | 10005517 | 1.65 | 72.4 | Curative (C) | 2016-11-17 | 2016-12-09 | Bortezomib + MELPHALAN | 02 | N | 10425847 | AML16 TRIAL |
| 10007657 | 10005519 | 1.66 | 85.7 | Palliative (P) | 2016-03-18 | 2016-08-13 | DA 3 + 10 | N | N | 10426222 | BORTEZOMIB |
| 10007658 | 10005519 | 1.62 | 61 | Palliative (P) | 2018-07-03 | 2018-11-05 | Cyclophosphamide + Docetaxel + Trastuzumab | N | N | 10426222 | FCR |
| 10007659 | 10005519 | null | 59.7 | Palliative (P) | 2018-02-06 | 2018-04-07 | Bortezomib +/- Dexamethasone | N | N | 10426222 | ERLOTINIB |
| 10007660 | 10005519 | 1.77 | 64.7 | Palliative (P) | 2017-11-05 | 2017-12-01 | Cyclophosphamide Weekly PO | N | N | 10426222 | TRIFLURIDINE + TIPIRACIL |